Morgan Stanley lowered the firm’s price target on Alvotech (ALVO) to $10 from $14 and keeps an Overweight rating on the shares. The firm sees the EU Pharmaceuticals sector set up as neutral into 2026, with fundamentals intact at a low valuation premium compared to history, offset by better EPS growth elsewhere in Europe, the analyst tells investors in a year-ahead outlook note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALVO:
- Alvotech’s AVT03 Biosimilar Gains European Approval
- Alvotech announces European Commission approval for AVT03
- Alvotech’s Gobivaz® Receives European Approval as First Simponi® Biosimilar
- Alvotech price target lowered to $10 from $13 at UBS
- Alvotech Reports Strong Revenue Growth and New Biosimilar Approvals